UBS Group
MGNX icon

UBS Group’s MacroGenics MGNX Stock Holding History

UBS Group’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,000
Closed -$65.8K – 10220
2024
Q3 		$65.8K Hold
20,000
– – ﹤0.01% 6646
2024
Q2 		$85K Buy
+20,000
New +$195K ﹤0.01% 6305

Other funds holding MGNX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

UBS Group's MGNX Position: Q1 2026 in Review

UBS Group increased its MacroGenics (MGNX) stake by 148% in Q1 2026, buying an estimated $377K and bringing the position to 296,086 shares worth $856K. The position accounts for ﹤0.01% of the portfolio, ranked #5668.

UBS Group first reported a position in MGNX in Q4 2014 and has held it in 46 quarters since. The position peaked at $3.8M in Q1 2024. 109 funds tracked by Wall St. Rank hold MGNX as of Q1 2026.

  • UBS Group held 296,086 shares of MacroGenics worth $856K as of Q1 2026.
  • UBS Group bought 176,639 MacroGenics shares in Q1 2026, an estimated $377K.
  • MacroGenics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5668 holding.
  • UBS Group first reported a position in MacroGenics in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's MacroGenics position peaked at $3.8M in Q1 2024.
  • 109 funds tracked by Wall St. Rank held MacroGenics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.